Assertio Holdings shares surge 12.51% premarket after Q3 earnings beat driven by Rolvedon sales and strong revenue growth.

Assertio Holdings surged 12.51% in premarket trading following the release of strong Q3 2025 earnings results, driven by a 130% year-over-year increase in Rolvedon sales to $38.6 million, which propelled total revenue to $49.5 million (a 79% beat on estimates). The company reported a net income of $11.4 million, reversing a prior-year loss, and maintained a 43% market share in Rolvidon’s key segment. Management highlighted supply stability via a long-term agreement with Omni and a robust cash position of $93.4 million. While challenges like generic competition for Indocin and near-term cash flow declines were noted, the earnings beat and updated guidance (narrowed to $110–$112 million in product sales) signaled operational strength. A director’s insider sale and executive promotion were less impactful compared to the earnings-driven optimism.